DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Silver Spring, MD 20993

ANDA 203790

ANDA APPROVAL

Actavis Mid Atlantic LLC
200 Elmora Avenue
Elizabeth, NJ 07207
Attention: Elizabeth Trowbridge, R.A.C.
Director of Regulatory Affairs

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) dated December 30, 2011, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), for Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%.

Reference is made to the Tentative Approval Letter issued by this office on April 6, 2015, and to your amendments dated May 7, August 21, and September 4, 2015.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the **ANDA is approved**, effective on the date of this letter. The Division of Bioequivalence has determined your Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug (RLD), Epiduo Topical Gel of Galderma Laboratories, L.P. (Galderma).

The RLD upon which you have based your ANDA, Galderma's Epiduo Topical Gel, is subject to periods of patent protection. The following patents and expiration dates are currently listed in the agency's publication titled Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book"):

U.S. Patent Number	Expiration Date
7,820,186 (the '186 patent)	November 23, 2025
7,964,202 (the '202 patent)	September 1, 2024
8,071,644 (the '644 patent)	July 18, 2027
8,080,537 (the '537 patent)	July 18, 2027
8,105,618 (the '618 patent)	December 23, 2022
8,129,362 (the '362 patent)	July 18, 2027
8,241,649 (the '649 patent)	December 23, 2022
8,445,543 (the '543 patent)	July 12, 2027
8,809,305 (the '305 patent)	December 23, 2022
8,936,800 (the '800 patent)	December 23, 2022

With respect to the '186, '202, '644, '537, '618, '362, '649 and '543 patents, your ANDA contains paragraph IV certifications under section 505(j)(2)(A)(vii)(IV) of the FD&C Act stating that each of these patents is invalid, unenforceable, or will not be infringed by your manufacture, use, or sale of Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%, under this ANDA. You have notified the agency that Actavis Mid Atlantic LLC (Actavis) complied with the requirements of section 505(j)(2)(B) of the FD&C Act, and litigation for infringement of the '186, '202, '644, '537, '618, and '362 patents was brought against Actavis within the statutory 45-day period in the United States District Court for the Northern District of Texas Dallas Division [Galderma Laboratories, L.P., Galderma S.A., and Galderma Research & Development, S.N.C. v. Actavis Mid Atlantic LLC, Civil Action No. 3:12-cv-2038].[1] You have notified the agency that the case was dismissed.

With respect to 180-day generic drug exclusivity, we note that Actavis was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification. Therefore, with this approval, Actavis is eligible for 180 days of generic drug exclusivity for Adapalene and Benzoyl Peroxide Gel, 0.1%/2.5%. This exclusivity, which is provided for under section 505(j)(5)(B)(iv) of the FD&C Act, will begin to run from the date of the commercial marketing identified in section 505(j)(5)(B)(iv). Please submit correspondence to this ANDA informing the agency of the date the exclusivity begins to run.

Under section 506A of the FD&C Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

Please note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS. See section 505-1(i) of the FD&C Act.

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert(s) directly to:

[1] The '649 and '543 patents were not listed in the Orange Book when your ANDA was received, and your paragraph IV certifications were submitted in an amendment to your ANDA. Under section 505(j)(5)(B)(iii) of the FD&C Act, litigation, if any, with respect to these patents would not be a bar to approval of your ANDA. We also note that the '305 and '800 patents were late-listed, and pursuant to 21 CFR 314.94(a)(12)(vi) do not need to be addressed.

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Office of Prescription Drug Promotion with a completed Form FDA 2253 at the time of their initial use.

The Generic Drug User Fee Amendments of 2012 (GDUFA) (Public Law 112-144, Title III) established certain provisions with respect to self-identification of facilities and payment of annual facility fees. Your ANDA identifies at least one facility that is subject to the self-identification requirement and payment of an annual facility fee. Self-identification must occur by June 1 of each year for the next fiscal year. Facility fees must be paid each year by the date specified in the Federal Register notice announcing facility fee amounts. All finished dosage forms (FDFs) or active pharmaceutical ingredients (APIs) manufactured in a facility that has not met its obligations to self-identify or to pay fees when they are due will be deemed misbranded. This means that it will be a violation of federal law to ship these products in interstate commerce or to import them into the United States. Such violations can result in prosecution of those responsible, injunctions, or seizures of misbranded products. Products misbranded because of failure to self-identify or pay facility fees are subject to being denied entry into the United States.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical in content to the approved labeling (including the package insert, and any patient package insert and/or Medication Guide that may be required). Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf. The SPL will be accessible via publicly available labeling repositories.

Sincerely yours,

William P. Rickman -S

Digitally signed by William P. Rickman -S
DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, 0.9.2342.19200300.100.1.1=1300043242, cn=William P. Rickman -S
Date: 2015.09.30 14:01:27 -04'00'

For Carol A. Holquist, RPh
Acting Deputy Director
Office of Regulatory Operations
Office of Generic Drugs
Center for Drug Evaluation and Research